Stay updated on Nivolumab Combo in BCG Unresponsive Bladder Cancer Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Combo in BCG Unresponsive Bladder Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Combo in BCG Unresponsive Bladder Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The website footer revision changed from v3.8.0 to v3.8.1.
    Difference
    0.0%
    Check dated 2026-11-18T00:28:39.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The page displays the ClinicalTrials.gov record for the nivolumab-based bladder cancer study, including its terminated status, eligibility criteria, treatment arms, outcomes, and participating locations. It also provides the study protocol and links to Bristol-Myers Squibb trial resources.
    Difference
    100%
    Check dated 2026-11-10T18:11:54.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0, while the study page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T18:35:47.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    A site-wide NIH banner announces the transition from “Artificial Intelligence” to “Super Intelligence” terminology. The ClinicalTrials.gov revision identifier also changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T19:07:26.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The page remains a 403 Forbidden error page; the footer revision identifier changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-06T20:11:20.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    Access to the study record is blocked by a 403 error, replacing the usual study details with a forbidden page. This prevents users from viewing the trial's overview, eligibility criteria, and locations, which are central to the page's function.
    Difference
    19%
    Check dated 2026-09-22T22:27:34.000Z thumbnail image

Stay in the know with updates to Nivolumab Combo in BCG Unresponsive Bladder Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Combo in BCG Unresponsive Bladder Cancer Clinical Trial page.